Expansion Footprint Millstone Medical is actively expanding its testing services footprint, including new facilities in Bloomfield Connecticut and New Jersey. This suggests sales opportunities for additional post-manufacturing capabilities, environmental and product testing, and potential cross-sell of warehousing and distribution services to broaden geographic coverage.

Testing Services Growth The launch and ongoing investment in Millstone Testing Services indicate a strong demand for contract testing across medical device and pharmaceutical products. Target prospects could include device manufacturers seeking compliant testing, packaging validation, and environmental testing to accelerate time-to-market and ensure quality.

Acquisition Momentum The acquisition of Ethide Laboratories in 2022 and subsequent expansion efforts signal a inorganic growth strategy that broadens capabilities. This presents an opportunity to position Millstone as a one-stop partner for post-manufacturing, testing, and reverse logistics to manufacturers looking to consolidate vendors.

Quality and Compliance Focus With services centered on quality, compliance, clean room packaging, and regulatory-aligned testing, Millstone aligns with manufacturers prioritizing risk management and regulatory readiness. This creates up-sell potential for audit-ready documentation, remediation services, and ongoing quality assurance programs.

Financials and Scale Annual revenue in the mid to high tens of millions and a 200–500 employee base position Millstone as a mid-market partner capable of handling sizable post-manufacturing programs. This enables targeting of mid-sized medical device firms seeking scalable, reliable post-manufacturing and aftermarket support without engaging large ERP-level vendors.